Daniel Canfield

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia

Lindsey T. Brinton, J. Byrd, J. Blachly, 2020, Cancers.

Targeting OXPHOS de novo purine synthesis as the nexus of FLT3 inhibitor–mediated synergistic antileukemic actions

J. Blachly, R. Baiocchi, D. Sampath, 2022, Science advances.

Porous-Coated Segmental Prosthesis for Large Tumor Defects

M. Malawer, I. Meller, Daniel Canfield, 1989 .

Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia

J. Byrd, J. Blachly, Pu Zhang, 2020, Journal of Hematology & Oncology.

Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: A phase I study.

S. Baker, A. Ruppert, K. Rogers, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition

J. Byrd, S. Kulp, J. Blachly, 2021, Clinical Cancer Research.